Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone ISM in Schizophrenia (PRISMA-3 OLE)
NCT03870880Phase 3Completed
- Sponsor
- Laboratorios Farmacéuticos ROVI
- Start
- Aug 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of risperidone in schizophrenia, sponsored by Laboratorios Farmacéuticos ROVI. Started Aug 2017; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03870880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870880.